Publications by authors named "Michal Fresser"
Article Synopsis
- Tau pathology is closely linked to cognitive decline in Alzheimer's disease (AD), prompting the development of tau-targeting immunotherapies like AADvac1, aimed at halting disease progression.
- The ADAMANT clinical trial evaluated AADvac1 in a subgroup of mild AD participants with elevated plasma p-tau217 levels over 24 months, focusing on safety and several cognitive and biological outcome measures.
- Results showed AADvac1 was safe and well-tolerated, significantly reduced levels of plasma neurofilament light and glial fibrillary acidic protein, and had a favorable—though not statistically significant—impact on cognitive scores and brain tissue preservation in certain regions, particularly in older participants.
Background: Tau pathology correlates with and predicts clinical decline in Alzheimer's disease. Approved tau-targeted therapies are not available.
Methods: ADAMANT, a 24-month randomised, placebo-controlled, parallel-group, double-blinded, multicenter, Phase 2 clinical trial (EudraCT2015-000630-30, NCT02579252) enrolled 196 participants with Alzheimer's disease; 119 are included in this post-hoc subgroup analysis.
Background: The emergence of new SARS-CoV-2 variants of concern B.1.1.
View Article and Find Full Text PDFArticle Synopsis
- - The ADAMANT trial studied AADvac1, a new vaccine targeting abnormal tau protein in Alzheimer’s disease, administered as 11 doses to patients with mild dementia over 24 months, focusing on safety, tolerability, and effectiveness.
- - A total of 196 participants were enrolled, with AADvac1 found to be safe and well tolerated, showing some adverse events but lower serious cases compared to placebo.
- - Although the vaccine stimulated a strong immune response, there were no significant improvements in cognitive function or clinical outcomes across the entire study group, indicating a need for more extensive research in specific subgroups to assess its efficacy.